Latest news with #RebeccaGrant
Fox News
27-05-2025
- General
- Fox News
Evening Edition: President Trump Warns Putin He Is ‘Playing With Fire'
President Trump unloading on Russian President Putin calling him 'absolutely crazy' in a social media post after attempts to end the war have failed. The comments come in what looks like an apparent change in approach to the Kremlin for the administration. Over the weekend Russia battered Ukraine with one of the largest attacks in months, with thousands of missiles and drones being launched at thirty different cities killing at least a dozen people. FOX's John Saucier speaks with Dr. Rebecca Grant, Vice President of the Lexington Institute and national security analyst, who says Putin is gambling the United States, and other allies, will stop giving Ukraine aid but he is wrong. Click Here To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit
Fox News
15-05-2025
- Business
- Fox News
Evening Edition: Why The President's Middle East Deals Are A Big Deal
President Trump is wrapping up his Middle East tour today with a visit to the United Arab Emirates. Along the way, he spent a whole day visiting the Gulf Arab state of Qatar. The royal house of Thani rules the tiny but oil-rich nation. While some know it for playing host to the U.S. military ever since the days after the September 11th attacks, the state is often criticized for its closeness to extremist groups. However, despite the complicated relationship, this week, President Trump said Qatar will invest tens of billions in the U.S. tech and defense sectors and will buy more than a hundred brand-new jets from Boeing. National Security Analyst, former Pentagon Staffer, and Iris Independent Research President Dr Rebecca Grant breaks down America's complex relationship with Qatar, and explains why America must make deals with the nation Learn more about your ad choices. Visit
Technical.ly
09-05-2025
- Business
- Technical.ly
Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics. Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large. 'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.' Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene. From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors. 'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said. Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia. Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative. 'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Yahoo
17-04-2025
- Business
- Yahoo
If Boeing Drops the Ball on the F-47, This Giant Defense Stock Should Take the Contract
It's been less than a month now since Boeing's (NYSE: BA) big news: On March 31, President Donald Trump announced that Boeing has won a $20 billion contract (that's the expected minimum value) to build the U.S. Air Force's first-ever sixth-generation stealth fighter to be known as the F-47. In the weeks that have followed this announcement, which drove Boeing stock as high as $182 a share, the stock price has slumped considerably. Granted, most of the damage was probably done by the stock market's tariffs tantrum of early April. But still, when you consider that the F-47 contract will be worth billions of dollars to Boeing over the next few years, and could grow in value into the hundreds of billions of dollars over time, that fact that Boeing stock is now trading more than 10% below what it cost before the F-47 news broke... well, it's kind of a puzzler. Why aren't investors giving Boeing more credit for its big defense contract win? To understand why investors might be hesitant to reward Boeing fully for its victory, consider the company's history of fumbling the ball on similar high profile government contracts. In 2014, for example, Boeing stood alongside SpaceX as one of just two space companies picked to provide Commercial Crew service transporting astronauts to and from the International Space Station. More than a decade later, SpaceX has flown astronauts to ISS nearly a dozen times already. Boeing has done so just once -- and then had to ask SpaceX for assistance getting its astronauts home again! Or consider the case of Boeing's 2011 win on the KC-X Tanker contract. Worth tens of billions, this award eventually turned into the KC-46 Pegasus contract for Boeing. But over the more than a decade that Boeing has been churning out the Pegasus for the Air Force, it's been forced to record more than $7 billion worth of losses on the program. Simply put, Boeing has a long history of snatching defeat from the jaws of victory, and turning potentially lucrative contracts into PR and balance sheet nightmares through a combination of underbidding and poor program management. It's in this context that I took note last month of the surprisingly better performance produced by one of Boeing's biggest rivals on high profile military contracts like the F-47: Northrop Grumman (NYSE: NOC). In a column carried by Lexington Institute Vice President Dr. Rebecca Grant praised Northrop's performance on its $55 billion contract to build 100 B-21 stealth bombers for the Air Force, which is now entering its 10th year. "Smooth progress on the production line enabled the Air Force to negotiate lower rates for the B-21 bombers now in production," says Grant, citing $1 billion in cost reductions for building B-21s under the Pentagon's 2025 budget. Total costs over the next five years could be as much as 28% below initial forecasts. Note, however, that the bomber's original projected unit cost of $550 million in 2010 dollars has increased in nominal terms. In todays, inflation adjusted dollars, the unit cost is now expected to approximate $692 million. "Coming in under budget is a first for a stealth aircraft," as Grant points out. Just as remarkable is that the B-21 program is running on time, and not behind schedule. Northrop produced its first "production-representative" prototype in late 2022, and conducted its first test flight of the B-21 in late 2023. Low rate initial production of the aircraft began shortly thereafter, in January 2024, and Northrop has already been awarded contracts to build two production "lots" of aircraft. It's in the context of all the above that I began to wonder: What happens if cost overruns begin to run... "over" at Boeing on its F-47 stealth fighter contract, while figuratively next door, Northrop Grumman continues to churn out B-21 stealth bombers at below-estimated cost? Might the Air Force decide to terminate the one contract, and hand it over to the better contractor? Stranger things have happened. Already we're seeing the Space Force begin to favor contract awards to SpaceX, for example, over contracts to Boeing and its United Launch Alliance joint venture with Lockheed Martin. Whether or not this is how things play out, defense investors already have good reason to favor Northrop Grumman stock over Boeing. According to data from S&P Global Market Intelligence, Northrop is: Profitable at $4.2 billion in trailing earnings, versus unprofitable Boeing (negative $11.8 billion). Free cash flow positive with $2.6 billion in trailing FCF, versus cash-burning Boeing (negative $14.3 billion). Northrop has less than half of Boeing's debt ($14 billion net of cash on hand, versus $29.6 billion). Why, Northrop even pays a dividend! Not much, just 1.6%. But Boeing pays no dividend at all. I won't say Northrop Grumman is the best investment on the planet. In fact, by my admittedly conservative metrics, the stock still looks a little expensive. But if you're in the market for a defense stock in particular, you could still do a lot worse than buying Northrop Grumman stock. Before you buy stock in Northrop Grumman, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Northrop Grumman wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor's total average return is 800% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy. If Boeing Drops the Ball on the F-47, This Giant Defense Stock Should Take the Contract was originally published by The Motley Fool Sign in to access your portfolio
Bloomberg
22-03-2025
- Business
- Bloomberg
US, Ukraine Talks Resume Early Next Week
"Balance of Power" focuses on the intersection of politics and global business. On today's show, Dr. Rebecca Grant, Vice President of Defense Programs at the Lexington Institute, discusses Boeing winning a multi-billion dollar contract to design and build the next-generation fighter jet and states this new fighter jet should be able to prevent a war with China. Jane Harman, Former Chair of the Commissioner on National Defense Strategy, discusses what she expects Ukraine and the United States to speak about as the two countries are set to talk with one another early next week. (Source: Bloomberg)
